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Résumé en
anglais
Parkinson plus diseases, comprising mainly progressive supranuclear palsy (PSP)
and multiple system atrophy (MSA) are rare neurodegenerative conditions. We
designed a double-blind randomized placebo-controlled trial of riluzole as a potential
disease-modifying agent in Parkinson plus disorders (NNIPPS: Neuroprotection and
Natural History in Parkinson Plus Syndromes). We analysed the accuracy of our
clinical diagnostic criteria, and studied prognostic factors for survival. Patients with
an akinetic-rigid syndrome diagnosed as having PSP or MSA according to modified
consensus diagnostic criteria were considered for inclusion. The psychometric
validity (convergent and predictive) of the NNIPPS diagnostic criteria were tested
prospectively by clinical and pathological assessments. The study was powered to
detect a 40% decrease in relative risk of death within PSP or MSA strata. Patients
were randomized to riluzole or matched placebo daily and followed up to 36 months.
The primary endpoint was survival. Secondary efficacy outcomes were rates of
disease progression assessed by functional measures. A total of 767 patients were
randomized and 760 qualified for the Intent to Treat (ITT) analysis, stratified at entry
as PSP (362 patients) or MSA (398 patients). Median follow-up was 1095 days (range
249–1095). During the study, 342 patients died and 112 brains were examined for
pathology. NNIPPS diagnostic criteria showed for both PSP and MSA excellent
convergent validity with the investigators’ assessment of diagnostic probability
(point-biserial correlation: MSA rpb = 0.93, P < 0.0001; PSP, rpb = 0.95, P <
0.0001), and excellent predictive validity against histopathology [sensitivity and
specificity (95% CI) for PSP 0.95 (0.88–0.98) and 0.84 (0.77–0.87); and for MSA 0.96
(0.88–0.99) and 0.91 (0.86–0.93)]. There was no evidence of a drug effect on survival
in the PSP or MSA strata (3 year Kaplan–Meier estimates PSP-riluzole: 0.51, PSP-
placebo: 0.50; MSA-riluzole: 0.53, MSA-placebo: 0.58; P = 0.66 and P = 0.48 by the
log-rank test, respectively), or in the population as a whole (P = 0.42, by the
stratified-log-rank test). Likewise, rate of progression was similar in both treatment
groups. There were no unexpected adverse effects of riluzole, and no significant
safety concerns. Riluzole did not have a significant effect on survival or rate of
functional deterioration in PSP or MSA, although the study reached over 80% power
to detect the hypothesized drug effect within strata. The NNIPPS diagnostic criteria
were consistent and valid. They can be used to distinguish between PSP and MSA
with high accuracy, and should facilitate research into these conditions relatively
early in their evolution.
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